Biotech and Pharmaceuticals Pharmaceuticals

More

  • *Forecast for 2016 profit growth defies analyst expectations. *Sees significant income from Uptravi after January launch. ZURICH, Feb 9- Actelion, Europe's largest biotechnology company, forecast that its core earnings would grow in 2016, defying concerns about rising generic competition in its main pulmonary arterial hypertension drug business.

  • Sanofi reports flat 2015 earnings Tuesday, 9 Feb 2016 | 4:31 AM ET

    PARIS— French drug maker Sanofi says its bottom line was roughly stable last year as it advanced efforts to reshape its drug portfolio and pursue research and development tie-ups in oncology and diabetes. Sanofi made 4.29 billion euros last year, compared to 4.39 billion in 2014. In December Sanofi and German pharmaceutical company Boehringer Ingelheim said...

  • Rio Olympics: Zika scare sparks warnings Tuesday, 9 Feb 2016 | 3:53 AM ET
    Aedes aegypti mosquitos known to carry the Zika virus.

    Kenya could pull out of this year's Rio Olympics due to concerns over the Zika virus outbreak in Brazil, the head of Kenya's Olympics committee said.

  • 2015 has been a fantasic year: Actelion CEO Tuesday, 9 Feb 2016 | 1:28 AM ET
    2015 has been a fantasic year: Actelion CEO

    Jean-Paul Clozel, CEO of Actelion, says 2015 may be the company's best year, with sales crossing 2 billion Swiss francs thanks to the drug Opsumit.

  • Drug prices jumped about 13 percent in the United States last year, spurring a public outcry and moving the issue onto the campaign platform of Hillary Clinton and other U.S. presidential candidates for the November 2016 election. The agreement applies to Cigna's commercial business and does not apply to its Medicaid or Medicare plans. Entresto, which costs...

  • NEW YORK, Feb 8- Pernix Therapeutics Holdings Inc, a U.S. specialty pharmaceutical company, is exploring strategic alternatives, including a potential sale, people familiar with the matter said on Monday. The Morristown, New Jersey- based drugmaker is working with investment bank Perella Weinberg Partners LP, the people said. Pernix shares jumped as much as 17...

  • Feb 8- Pernix Therapeutics Holdings Inc, a U.S. specialty pharmaceutical company, is exploring strategic alternatives, including a potential sale, people familiar with the matter said on Monday. The Morristown, New Jersey- based drugmaker is working with investment bank Perella Weinberg Partners LP, the people said. The process is still in its early stages and...

  • *Drug fails to beat placebo in mid-stage trial. Feb 8- BioCryst Pharmaceuticals Inc said its lead drug failed to reduce the frequency of recurrent swelling in patients with hereditary angioedema, sending its shares skidding as much as 68 percent in early trading on Monday. The results will clearly work in the favor of British drugmaker Shire Plc, which has two...

  • Feb 5- A federal judge on Friday said Allergan Plc's planned generic version of a drug meant to treat epilepsy infringed patents belonging to Supernus Pharmaceuticals Inc.. They closed up $2.00, or 19.7 percent, at $12.13 on the Nasdaq. District Judge Renée Marie Bumb in Camden, New Jersey said Allergan's proposed generic infringed two of the three Supernus...

  • Supernus beats Allergan over epilepsy drug patents Friday, 5 Feb 2016 | 3:32 PM ET

    Feb 5- A federal judge on Friday said Allergan Plc's plan to sell a generic version of a drug meant to treat epilepsy infringed patents belonging to Supernus Pharmaceuticals Inc.. District Judge Renée Marie Bumb in Camden, New Jersey said the proposed generic version of Oxtellar XR infringed two of three Supernus patents in question. In afternoon trading,...

  • The news sent shares of J&J, whose annual Remicade sales of $6.5 billion are mostly in the United States, down more than 3 percent. FDA scientists released their favorable report ahead of a scheduled meeting on Tuesday of an independent medical advisory panel to the agency. "In considering the totality of the evidence, the data submitted by Celltrion show that is...

  • FDA scientists released their supportive findings ahead of a scheduled meeting on Tuesday of an independent medical advisory panel to the agency. "In considering the totality of the evidence, the data submitted by Celltrion show that is highly similar to U.S.-licensed Remicade" in treatment of rheumatoid arthritis and a related condition called...

  • FDA scientists early on Friday released their supportive findings ahead of a scheduled meeting on Tuesday of an independent medical advisory panel to the agency. South Korea's Celltrion and partner Pfizer Inc want to sell Remsima in the United States as a cut-price copy of Johnson& Johnson and Merck& Co's Remicade, or infliximab, which had global 2014 sales of...

  • Feb 4- U.S. Food and Drug Administration staff members on Friday said clinical data from Celltrion Inc's biosimilar form of blockbuster arthritis drug Remicade indicated it is "highly similar" to the branded product in terms of safety, purity and potency. FDA scientists released their supportive findings ahead of a scheduled meeting on Tuesday of an...

  • Robert Califf, President Barack Obama's nominee to lead the Food and Drug Administration, said on Thursday the agency would reform its process for approving opioid painkillers. The FDA said it has agreed to convene a committee before approving any new opioid that does not have abuse-deterrent properties. Califf, who joined the FDA a year ago as a deputy...

  • Merrimack CEO: Face of pharma isn't a bad actor Thursday, 4 Feb 2016 | 2:14 PM ET
    Merrimack CEO: Face of pharma isn't a bad actor

    Merrimack Pharmaceuticals develops products to treat cancer. President and CEO Bob Mulroy, shares his view of drug price hikes and whether the FDA is in the way of companies.

  • Chaffetz: 'Sort of childlike' behavior from Shkreli Thursday, 4 Feb 2016 | 1:55 PM ET
    Chaffetz: 'Sort of childlike' behavior from Shkreli

    Rep. Jason Chaffetz (R-Utah), Chairman of the House Oversight & Government Committee, comments on former Turing Pharmaceuticals CEO Martin Shkreli's tweet calling the Congressional committee "imbeciles."

  • Chaffetz: Believe in profit, but I take issue with misrepresenting drugs

    Rep. Jason Chaffetz (R-Utah), Chairman of the House Oversight & Government Committee, reflects on former Turing Pharmaceuticals CEO Martin Shkreli's behavior on Capitol Hill, and the debate on drug prices and the role of government.

  • Martin Shkreli takes on Congress Thursday, 4 Feb 2016 | 12:12 PM ET
    Martin Shkreli, former CEO of Turing Pharmaceuticals, prepares to testify before a House Oversight and Government Reform hearing on Capitol Hill, Feb. 4, 2016.

    Martin Shkreli, the former drug company CEO who's come under fire for massive drug price increases, refused to testify Thursday before a congressional committee investigating drug price hikes.

  • Martin Shkreli on the Hill Thursday, 4 Feb 2016 | 9:20 AM ET
    Martin Shkreli on the Hill

    House Oversight Chairman Jason Chaffetz swears in the panel at the House Oversight Committee hearing on drug price hikes, where former Turing Pharmaceuticals CEO Martin Shkreli is testifying.